← Human Trials & Peer-Reviewed Studies
The effects of angiotensin II receptor blockade with losartan on systemic blood pressure and renal and extrarenal prostaglandin synthesis in women with essential hypertension
Plain-language guide to PMID 8998251 (1995): single-blind and placebo-controlled clinical trial study of Angiotensin II, low blood pressure and orthostatic hypotension.
Key Facts
- PMID
- 8998251
- Journal
- American journal of hypertension
- Year
- 1995
- Study type
- Clinical Trial
- Authors
- Smith MC et al. (7 authors)
- DOI
- 10.1016/0895-7061(95)00361-4
What This Study Did, in Plain Language
What Was Tested
Researchers studied Angiotensin II in the context of low blood pressure and orthostatic hypotension in this clinical trial publication.
Sixteen postmenopausal women with essential hypertension, with a mean age of 59 years and diastolic blood pressures of 95 to 115 mm Hg, were enrolled in a 12-week, single-blind study to determine the effects of losartan on blood pressure, renal and extrarenal PG production, plasma renin activity (PRA), plasma aldosterone, and routine biochemical parameters.
Why It Was Studied
The major antihypertensive effect of losartan, a nonpeptide angiotensin II antagonist, is thought to be due to inhibition of the pressor effects of angiotensin II.
It is possible, however, that losartan alters the synthesis of vasodilator or vasoconstrictor prostaglandins (PG), thus contributing to its antihypertensive effect.
Who Took Part
The age groups tagged for this paper are middle-aged adults and older adults, women only.
How the Study Was Run
The design is described as single-blind and placebo-controlled.
Only one side, usually the participants, was kept unaware of whether Angiotensin II was given.
Some participants received a placebo instead of Angiotensin II, giving a reference point.
The timeline in the abstract includes 4 weeks.
What Was Measured
Topics PubMed links to this paper include Aldosterone, Angiotensin II, Angiotensin Receptor Antagonists, Antihypertensive Agents, Biphenyl Compounds, Blood Pressure and Hypertension.
What This Means in Plain Language
The paper is a single-blind and placebo-controlled study of Angiotensin II in people with low blood pressure and orthostatic hypotension over 4 weeks.
The publication is from 1995 (American journal of hypertension), a journal based in United States.
More context: the Angiotensin II compound page, Low blood pressure and orthostatic hypotension research.
Our Notes on the Compound
Angiotensin II: An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.